Highlighted Webinar
Discover our most watched webinar and learn groundbreaking insights from Prof. Marcela Maus
Cell Avidity Measurements to Understand and Enhance CAR-T/Tumor Interactions in Acute Myeloid Leukemia
Dr. Marcela Maus used avidity measurements to understand and enhance productive CAR-T cell interactions.
On-demand Webinars
Uncover a range of on-demand webinars delivered by our application scientists or invited speakers on a wide range of topics.
Cell avidity as a crucial biomarker for CAR T response
Dr. Rebecca Larson’s work revealed important evasion mechanism from CAR T cell response in solid tumors.
Enhanced avidity through combining a BCMA CAR and a CD38 chimeric costimulatory receptor leads to T-cell sensitivity to low antigen density and promotes persistence
Dr. Maria Themeli showed how to overcome low antigen density and improve CAR-T cell persistence with multi-targeting and co-stimulation.
Exploring the network of cellular interactions of Natural Killer cells in the tumor microenvironment with cell avidity
Prof. Mark Lowdell discussed how primed NK cells become effective in resistant tumor cell killing through stronger binding.
Dual-targeted cell therapy targeting BCMA and GPRCD5 to prevent relapse in multiple myeloma
Prof. de Larrea demonstrated reduced relapse through dual-targeting CAR T approaches.
Unveiling a one-to-one relationship of TCR-dependent T cell function and cellular avidity at single-cell level using acoustic force
The cell avidity experiments provided for the team of Dr. Nathalie Rufer shows a better in vivo correlation.
TCR- and BsAb-induced interaction drives avidity-based cellular immunotherapy efficacy
Cell avidity measures the effectiveness of the events during immunological synapse formation.
How cell avidity between tumor-effector cell pairs drives the efficacy of cellular immunotherapy
Measuring cell avidity provides a more complete and physiologically relevant picture of the cell-cell interaction.
Cell avidity of CAR-NK cells revealed as the best and earliest predictive parameter for 𝙞𝙣 𝙫𝙞𝙫𝙤 tumor control
Dr. Peter Chockley demonstrates how cell avidity measurements directly linked to synapse quality and in vivo tumor clearance using CAR-NK avidity-tuned cells
© 2024 LUMICKS.
Specifications and equipment are subject to change without any notice or obligation on the part of the manufacturer.
Privacy Policy | Code of Conduct
Download our webinar recording:
Download our Cell Therapy (CAR-T, TCR, NK) applications deck
